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Abstract
Objective: Inhibitors of the voltage-gated K+ channel Kv1.3 are currently in
development as immunomodulators for the treatment of autoimmune diseases.
As Kv1.3 is also expressed on microglia and has been shown to be specifically up-
regulated on “M1-like” microglia, we here tested the therapeutic hypothesis that
the brain-penetrant small-molecule Kv1.3-inhibitor PAP-1 reduces secondary
inflammatory damage after ischemia/reperfusion. Methods: We studied micro-
glial Kv1.3 expression using electrophysiology and immunohistochemistry, and
evaluated PAP-1 in hypoxia-exposed organotypic hippocampal slices and in mid-
dle cerebral artery occlusion (MCAO) with 8 days of reperfusion in both adult
male C57BL/6J mice (60 min MCAO) and adult male Wistar rats (90 min
MCAO). In both models, PAP-1 administration was started 12 h after reperfu-
sion. Results: We observed Kv1.3 staining on activated microglia in ischemic
infarcts in mice, rats, and humans and found higher Kv1.3 current densities in
acutely isolated microglia from the infarcted hemisphere than in microglia iso-
lated from the contralateral hemisphere of MCAO mice. PAP-1 reduced microglia
activation and increased neuronal survival in hypoxia-exposed hippocampal slices
as effectively as minocycline. In mouse MCAO, PAP-1 dose-dependently reduced
infarct area, improved neurological deficit score, and reduced brain levels of IL-
1b and IFN-c without affecting IL-10 and brain-derived nerve growth factor
(BDNF) levels or inhibiting ongoing phagocytosis. The beneficial effects on infarct
area and neurological deficit score were reproduced in rats providing confirma-
tion in a second species. Interpretation: Our findings suggest that Kv1.3 consti-
tutes a promising therapeutic target for preferentially inhibiting “M1-like”
inflammatory microglia/macrophage functions in ischemic stroke.
Introduction
The voltage-gated K+ channel Kv1.3 was first discovered in
human T-cells in 19841 and has since then been pursued as
a target for immunosuppression. After the channel was
cloned, the pharmaceutical industry initiated Kv1.3 discov-
ery programs in the mid-1990s but largely failed to identify
compounds that were suitable for development.2 Interest in
Kv1.3 afterward waned but revived following reports from
our group that Kv1.3 is overexpressed in activated CCR7
effector memory T-cells (TEM) and that Kv1.3 blockers
therefore constitute immunomodulators rather than gen-
eral immunosuppressants.3–5 Subsequent proof-of-concept
animal studies demonstrated that the Kv1.3 blocking sea
anemone Stichodactyla helianthus peptide ShK and its
derivatives treat rat models of multiple sclerosis and
rheumatoid arthritis,4–6 while our small molecule Kv1.3
blocker PAP-1 prevents autoimmune diabetes4 in rats and
treats psoriasis in a mouse xenograft model.7 As Kv1.3
blockers preferentially target TEM cells, Kv1.3 blockers do
not impair the ability to clear acute infections or develop
vaccine responses. For example, Kv1.3 blockers do not
affect the ability of rats to clear influenza virus and Chlamy-
dia trachomatis5 or prevent rhesus macaques from develop-
ing protective, flu-specific central memory T-cell responses
following immunization with a live influenza vaccine.8
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Based on these encouraging target validation studies, ShK-
186, now called Dalazatide, was moved into clinical trials,
where it exhibited no major safety findings in Phase-1a and
showed efficacy in Phase-1b studies in plaque psoriasis and
is now being developed further.9
In addition to T-cells, Kv1.3 is also expressed in micro-
glia, where in vitro experiments with rodent microglia
have shown the channel to be involved in inflammatory
cytokine and nitric oxide production and in microglia-
mediated neuronal killing.10–14 Electrophysiological exper-
iments on slices15 or acutely isolated microglia16 have fur-
ther demonstrated Kv1.3 currents on activated microglia
following MCAO. In humans, strong Kv1.3 staining has
been reported on microglia in the frontal cortex of
patients with Alzheimer’s disease17 and on CD68+ cells in
multiple sclerosis brain lesions.18 Using cultured neonatal
mouse microglia, our group recently demonstrated that
Kv1.3 expression increases following stimulation with the
M1-polarizing stimuli LPS or LPS plus IFN-c, while IL-4
stimulation induced a down-regulation of Kv1.3 and an
increase in currents for the inward-rectifier K+ channel
Kir2.1,19 suggesting that Kv1.3 blockers might be able to
preferentially target detrimental proinflammatory M1
microglia functions. We therefore hypothesized that
Kv1.3 blockers could be useful for ameliorating pathology
in ischemic stroke, where activated microglia significantly
contribute to the secondary expansion of the infarct.20,21
In order to test this therapeutic hypothesis, we here con-
firmed Kv1.3 expression on microglia in infarcted rodent
and human brain and then evaluated our small molecule
blocker PAP-122 first in organotypic brain slices and then
in middle cerebral artery occlusion (MCAO) with reper-
fusion. PAP-1 is currently the most potent and selective
small molecule Kv1.3 blocker available. It inhibits Kv1.3
with an IC50 of 2 nmol/L,
22 has a half-life of 3 h in
rodents, is orally available, brain penetrant and does not
exhibit any long-term toxicity in rodents or primates.4,8,23
Materials and Methods
Transient Focal Ischemia
This study was approved by the University of California,
Davis, Animal Use and Care Committee and conducted
in accordance with the guidelines for survival surgery.
Adult 12-week-old male C57BL/6J mice (Jackson Labora-
tory) or adult male Wistar rats (Charles River) were accli-
matized to the vivarium for a week and used for surgery
when they were 12–14 weeks old (mice) or weighed 200–
230 g (rats). Animals were anesthetized with 5% isoflu-
rane and then maintained on 0.5 to 1.5% isoflurane. To
assure consistent and continuous reduction in cerebral
blood flow (CBF), a laser Doppler (Moor Instruments)
was used throughout the surgery. Reversible focal cerebral
ischemia was induced by occlusion of the left middle
cerebral artery (MCA) according to Zea Longa.24 Briefly,
the left common carotid artery was exposed, the external
carotid artery ligated distally from the common carotid
artery, and a silicone rubber-coated nylon monofilament
with a tip diameter of 0.21  0.02 mm for mice and of
0.43  0.02 mm for rats (Doccol Corp.) inserted into the
external carotid artery and advanced into the internal car-
otid artery to block the origin of the MCA.24,25 The fila-
ment was kept in place for 60 min (mice) or 90 min
(rats) and then withdrawn. Animals received subcuta-
neous Buprenex at 0.02 mg/kg every 12 h to limit post-
surgical pain for 24 h after surgery. For sham surgeries,
the filament was placed into the external carotid artery
but not advanced into the internal carotid artery.
Four MCAO surgeries were performed per day. The
survival rate was 85% in mice and 90% in rats. Animals
where CBF was not reduced by at least 70% and which
did not display any obvious neurological deficit 12 h after
reperfusion were excluded. Animals that met these inclu-
sion criteria were assigned to treatment or vehicle groups
based on a computer-generated randomization scheme.
Based on our previous work with the KCa3.1 blocker
TRAM-34 in MCAO,16,25 sample size was powered to
detect a reduction of 40% in mean percentage infarct area
with 80% power. Starting 12 h after reperfusion animals
received the vehicle miglyol 812 neutral oil (Neobee M5,
Spectrum Chemicals) or PAP-1 at 10 or 40 mg/kg
intraperitoneally every 12 h until sacrifice on day-8. PAP-
1 was synthesized in our laboratory.22 Miglyol 812 is a
low viscosity oily vehicle, which is widely used as a phar-
maceutical excipient and well tolerated for i.p., s.c. or oral
administration. It can be autoclaved and allows for the
dissolution of lipophilic compounds like PAP-1 at high
concentrations (5 and 20 mg/mL for this study). Neuro-
logical deficits were scored according to a tactile and pro-
prioceptive limb-placing test26 as previously described.25
The investigator performing the drug administration and
neurological scoring was blinded to the treatments.
Infarct area
Animals were euthanized with an overdose of isoflurane,
brains quickly removed, and sectioned into four (mice)
or eight (rats) 2-mm thick coronal slices starting from
the frontal pole. Slices were fixed in 10% buffered forma-
lin for 24 h in order to make it possible to prepare
undamaged sections from the otherwise often brittle aged
infarcts. Slices were stored in 70% ethanol, embedded in
paraffin, and sectioned at 5 lm by the Histology Labora-
tory of the UC Davis School of Veterinary Medicine.
Infarct area was quantified in a blinded fashion by
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analyzing the NeuN-negative area using a pixel-based
method as previously described.16
Isolation of CD11b+ cells and
electrophysiology
CD11b+ cells from the infarct area were isolated as previ-
ously described.16,27 Briefly, mice were anesthetized with
isoflurane 2, 5, and 8 days after reperfusion MCAO and
killed by cervical dislocation. Brains were removed quickly
and the infarcted hemispheres dissected and kept in ice-cold
Hank’s balanced salt solution (HBSS) after removing cere-
bellum and brain stem. The brain tissue was chopped into
small pieces and centrifuged at 300 g for 2 min to remove
the supernatant. Following digestion with enzyme mix 1 for
15 min and enzyme mix 2 for 10 min at 37°C, brain tissue
was mechanically dissociated by pipetting up and down.
The tissue suspension was centrifuged at 300 g at 4°C for
10 min to spin down the cells. Magnetic microbeads conju-
gated to CD11b-antibody were added to the cell suspension,
and CD11b+ cells were isolated with the Miltenyi magnet
according to the manufacturer’s protocol (Miltenyi Biotec
Inc.). Acutely isolated microglia were over 94% pure
(CD11b+) based on flow cytometry assessments.
Acutely isolated CD11b+ cells were plated on poly-L-
lysine-coated glass coverslips immediately and then incu-
bated at 37°C for 10 min before electrophysiological
recordings. Overall, the isolation procedure lasted 90 min
from the removal of the brains until the microglia were on
the microscope stage ready to be patch-clamped. Currents
were recorded at room temperature using the whole-cell
configuration of the patch-clamp technique with an EPC-
10 HEKA amplifier. Normal Ringer solution (160 mmol/L
NaCl, 4.5 mmol/L KCl, 2 mmol/L CaCl2, 1 mmol/L
MgCl2, 10 mmol/L HEPES, pH 7.4, 300 mOsm) was used
as an external. Patch pipettes were filled with an internal
solution containing 145 mmol/L KF, 2 MgCl2, 10 mmol/L
HEPES, 10 EGTA (pH 7.2, 290 mOsm). K+ currents were
elicited with voltage ramps from 120 to 40 mV of 200-ms
duration or by voltage steps from 80 to +40 mV applied
every 30 sec.3 Access resistance was monitored continu-
ously and no series resistance compensation was used as
access resistances typically stayed below 10 MΩ. Kv1.3 cur-
rent densities were determined by dividing the current
amplitude at +40 mV by the cell capacitance.
Hippocampus slice culture and hypoxia
treatment
Hippocampal slice cultures (400 lm thick) were prepared
from 7-day-old C57BL/6J mice as described.28 After 3 days,
culture medium was changed to a hypoxic/hypoglycemic
medium (75% Neurobasal, 25% HBSS, 1% L-glutamine,
bubbled with 99.4% nitrogen). Slices were placed in a
hypoxia incubation chamber (Stemcell Technologies, Van-
couver), and nitrogen gas was flowed into the chamber, fol-
lowed by incubation at 37o for 1 h. The culture medium
was replaced by normal culture medium containing glu-
cose, and slices were placed in a tissue culture incubator.
After 2 h of culture, 1 lmol/L of PAP-1 or 10 lmol/L of
minocycline were added and slices cultured for 3 days.
Slices were fixed in 4% formaldehyde and stained with
anti-NeuN (1:400; Chemicon) and anti-Iba1 (1:400; Wako
Chemical) followed by secondary Alexa-Fluor488-conju-
gated anti-mouse or Alexa-Fluor568-conjugated anti-rab-
bit antibodies (1:700; Life Technologies). For Western
blotting, slices were lysed and protein electrophoresed and
visualized as previously described.14 The following primary
antibodies were used as follows: anti-PSD95 (1:1000) and
anti-GAPDH (1: 3000; both Cell Signaling Technology).
The secondary antibody was an HRP-conjugated anti-rab-
bit antibody (1:3000; Amersham Biosciences).
Immunohistochemical (IHC) and
immunofluorescence (IF) staining
All IHC or IF staining in this study was performed after
antigen retrieval (heating in 10 mmol/L Na citrate for
15 min). NeuN (1:1000, A60, Millipore) staining to assess
infarct area was performed as described.16 For the mouse
brain IF images in Figure 1A, Kv1.3 was stained with a
polyclonal anti-Kv1.3 antibody (1:300, APC-101, Alo-
mone) and Iba1 with a monoclonal anti-Iba1 antibody
(1:1000, NCNP24, Wako Chemical). For Figure 1B, CD68
was stained with a monoclonal anti-mouse CD68 anti-
body (1:200, FA-11, Bio-Rad) and Kv1.3 with a polyclonal
anti-Kv1.3 antibody (1:300, APC-002, Alomone). For Fig-
ure 1C, Kv1.3 was stained with a mouse monoclonal anti-
Kv1.3 antibody (1:300, 1D8, Bio-Rad) and iNOS with a
polyclonal rabbit antibody (1:100, ab3523, Abcam).
Bound primary antibodies were detected with Alexa-
Fluor546- or Alexa-Fluor647-conjugated secondary
antibodies (Life Technologies). The IHC staining for rat
CD68 in Figure 7A was performed as described.25
The human brain autopsies and the biopsy (Fig 3) were
obtained from the University of California Biorepository,
which provides sections from archived paraffin blocks for
research. The needle biopsy is a 7-day-old ischemic infarct
from a 37-year-old patient. The surgery was conducted due
to clinical uncertainty, and ischemic infarct was confirmed
by a board-certified neuropathologist (Dr. Lee-Way Jin).
Human macrophages/microglia were stained with mouse
anti-human macrophages antibody (1:100, MAC387, Bio-
Rad), Kv1.3 with a mouse monoclonal anti-Kv1.3 antibody
(1:100, 1D8, Bio-Rad) and iNOS with a polyclonal rabbit
antibody (1:100, ab3523, Abcam).
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Phagocytosis was evaluated by the association of CD68-
positive cells with TUNEL+ cells or the internalization of
TUNEL+ material. Paraffin sections of the infarct zone were
stained with rat anti-mouse CD68 antibody conjugated
with Alexa Fluor488 (1:200, FA-11, Bio-Rad) and In situ
BrdU-Red DNA Fragmentation (TUNEL) Assay Kit
(ab66110, Abcam). The percentage of CD68-positive cells
adjacent to TUNEL+ cells or containing TUNEL+ material
was calculated by analyzing confocal images with Image J.29
Brain cytokines
Cytokines (IFN-c, IL-1b, IL-6, IL-10, TNF-a), BDNF, and
TGF-b1 in brain extract were analyzed with Millipore
Milliplex mouse magnetic bead kits and a Luminex
200TM reader and the results normalized to pg/mg of
total protein content in each sample (assayed by the
bicinchoninic (BCA) procedure) as described.16
Statistical analyses
Statistical analysis of infarct area, neurological deficit
scoring, and IHC were performed with one-way analysis
of variance (ANOVA; Origin software) followed by post
hoc pair-wise comparison of the different groups using
Tukey’s method, also referred to as honestly significant
difference test, as recommended by Schlattmann and Dir-
nagl for MCAO studies.30 Shown are mean  S.E.M.
P < 0.05 was used as the level of significance. *=P < 0.05,
**=P < 0.01, ***=P < 0.001.
Results
Kv1.3 Expression in ischemic stroke
In order to investigate Kv1.3 expression in ischemic stroke,
we subjected adult male mice to reversible focal cerebral
ischemia induced by 60-min occlusion of the left middle
cerebral artery (MCA) and performed immunohistochem-
istry for Kv1.3 on brains removed 2, 5, and 8 days after
reperfusion. In normal rodent brain, Kv1.3 staining is most
prominent in mitral cells of the olfactory bulb31 and presy-
naptic terminals of brain stem auditory neurons,32 while
lower levels of Kv1.3 expression are observed in cortical
interneurons.33 However, compared to activated T-cells
and microglia in inflammatory lesions,18,34 neuronal Kv1.3
staining is typically faint and often only observable with
higher antibody concentrations and long incubation
times.33 In agreement with these findings, we did not note
any significant Kv1.3 staining on neurons, astrocytes, or
surveillant microglia in normal mouse brain (data not
shown) when using anti-Kv1.3 antibody concentrations
that stain activated lymphocytes in our hands.7,35
Following MCAO, staining with a polyclonal anti-Kv1.3
antibody directed against an extracellular epitope revealed
strong Kv1.3 immunoreactivity on hypertrophic Iba1+
microglia/macrophages in the infarct border of paraffin
sections prepared five and eight days after reperfusion
(Fig. 1A). Two days after MCAO, Iba1 and Kv1.3 staining
was fainter (Fig. 1A top) but started to be observable sug-
gesting that Kv1.3 expression in vivo increases following
microglia activation with a similar time course as
described in vitro following stimulation of microglia with
LPS or astrocyte conditioning medium.36 At the peak of
microglia activation on day-8, Kv1.3 expression was
found to be localized to cells positive for inducible nitric
oxide synthase (iNOS) and CD68 using both a polyclonal
and a monoclonal anti-Kv1.3 antibody directed against
the intracellular C-terminus of the channel (Fig. 1B,C).
We further subjected microglia/macrophages acutely iso-
lated with CD11b-mangetic beads to whole-cell patch-
clamp in order to directly study microglia Kv currents and
determine the contribution of Kv1.3 to the total Kv current
based on its pharmacological and biophysical properties. In
order to avoid contributions from calcium-activated K+
channels or chloride currents, we used a KF-based pipette
solution. While Kv current amplitudes were very low or
often barely detectable in microglia isolated from normal,
nonischemic brains (Fig. 2A), Kv current amplitudes
recorded from microglia isolated from the infarcted area
were significantly increased on day-2, day-5 and peaked on
day-8 after MCAO (Fig. 2D). The current was predomi-
nantly carried by Kv1.3 based on its threshold voltage of
activation around 40 mV, sensitivity to PAP-1 (Fig. 2B
and C) and its use-dependence (data not shown). When
current amplitudes were converted into current densities in
order to account for the increase in cell size during micro-
glia activation, Kv1.3 current density was significantly
higher on day-8 after MCAO compared to microglia iso-
lated from the contralateral side of the same animals or to
microglia from normal control brains (Fig 2E).
Kv1.3 expression Human Infarcts
In order to confirm that Kv1.3 is also expressed on human
microglia, we stained postmortem brain sections from
patients with vascular dementia, which contained microin-
farcts estimated to be roughly 2 weeks old, with the
Figure 1. Kv1.3 expression on microglia in the border zone of ischemic infarcts in mice. (A) Representative immunofluorescent staining showing
Iba1 and Kv1.3 expression 2, 5 and 8 days after MCAO with reperfusion. (B) Kv1.3 and CD68 or Kv1.3 and iNOS double staining 8 days after
MCAO with reperfusion.
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monoclonal anti-Kv1.3 antibody. Strong, positive Kv1.3
staining was localized to MAC387-positive microglia/
macrophages (Fig. 3A). We were further able to obtain a
needle biopsy sample from a 37-year-old patient, which
was conducted due to clinical uncertainty. A 7-day-old
ischemic infarct was confirmed by a board-certified neu-
ropathologist. The needle biopsy contained many clustered
MAC387-positive macrophages/microglia (not shown),
which stained positive for both Kv1.3 and iNOS (Fig. 3B).
Kv1.3 Inhibition reduces microglia
activation and increases neuronal survival
in organotypic hippocampal slices
As a first test of our hypothesis that Kv1.3 inhibition
could be beneficial in ischemic stroke, we investigated the
effect of PAP-1 on organotypic hippocampal slice cul-
tures. Hippocampal slices reflect conditions in the brain
in terms of microglia interactions with neurons and astro-
cytes but allow no additional monocytes or T-cells to
infiltrate from the blood. Exposure of hippocampal slices
to hypoxia/aglycemia for 60 min resulted in strong
microglia activation and a reduction in surviving NeuN+
neurons 3 days later as determined by Iba-1 and NeuN
staining (Fig. 4A). Treatment of slices with PAP-1 or the
microglia inhibitor minocycline resulted in a significant
increase in neuronal survival and a reduction in microglia
activation (Fig. 4A,B). PAP-1 further reduced the hypox-
ia-induced loss of PSD95 expression suggesting increased
preservation of excitatory synapses (Fig. 4C). PAP-1 is
unlikely to have exerted any direct neuroprotective effects
in this assay because experiments performed with PAP-1
Figure 2. Functional Kv1.3 channel expression on acutely isolated MCAO microglia. Representative whole-cell current traces showing Kv1.3 currents
recorded from microglia acutely isolated from either (A) normal control mouse brain, (B) day-2 ipsilateral MCAO mouse brain or (C) day-8 ipsilateral
MCAO mouse brain. (D) Scatterplot showing Kv1.3 current amplitude measured from individual microglial cells for each condition. A significant
increase in Kv1.3 current expression is observed starting on day-2 (51.41  29.24 pA, n = 12) and day-5 (41.78  26.49 pA, n = 19) on ipsilateral
microglia compared to normal control (14.46  8.60 pA, n = 15) and day-8 contralateral microglia (15.16  10.38 pA, n = 18). ***P < 0.001. Day-
8 ipsilateral microglia (154.53  94.46 pA, n = 32) express the largest Kv1.3 increase compared to all other conditions. ***P < 0.001. (E) Scatterplot
showing Kv1.3 current density calculated for individual microglial cells for each condition. A significant increase in Kv1.3 current density is observed
only in day-8 ipsilateral microglia (36.40  22.42 pA, n = 32) compared to normal control (5.06  3.77 pA, n = 15), day-2 ipsilateral (6.70  3.98
pA, n = 12), day-5 ipsilateral (5.27  4.08 pA, n = 19) and day-8 contralateral microglia (5.73  4.44 pA, n = 18). **P < 0.01. All values are
presented as mean  SD. The significance of the difference between two conditions was tested using two-tailed paired Student’s t-test.
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by the NIH Anticonvulsant Screening program did not
report any neuroprotection with 10 lmol/L of PAP-1 in
organotypic hippocampal slices (n = 8) exposed to
20 lmol/L of the excitotoxic agent kainic acid for 4 h
and evaluated for propidium iodide uptake in the CA1
and CA3 pyramidal cell layers and the dentate gyrus at
24 h.37 Taken together, these findings and their time
course confirm previous observations made with Kv1.3-
blocking peptides and LPS-stimulated microglia in Tran-
swell cell culture systems11 and suggest that Kv1.3 inhibi-
tion increases neuronal survival by reducing microglia-
mediated neuronal killing.
Kv1.3 blockade reduces infarction and
improves neurological deficit in middle
cerebral artery occlusion with reperfusion in
mice
As our Kv1.3 blocker PAP-1 penetrates well into the brain
(Cbrain/Cplasma = 1.1), we next used it as a pharmacologi-
cal tool in a mouse model of ischemic stroke. Adult male
C57BL/6J mice were subjected to reversible focal cerebral
ischemia induced by 60-min occlusion of the left MCA
and scored daily for neurological deficit until sacrifice on
day-8. Starting 12 h after reperfusion, mice were treated
Figure 3. Kv1.3 expression in human infarcts. (A) Double immunofluorescent staining for activated microglia/macrophages (MAC387) and Kv1.3
in a roughly 2-week-old microinfarct. (B) Staining for Kv1.3 and iNOS in a needle biopsy from a 37-year-old man 7 days after an ischemic stroke.
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intraperitoneally twice daily with either vehicle or the
Kv1.3 blocker PAP-1 at 10 or 40 mg/kg. PAP-1 treated
mice exhibited a significant reduction in infarct area as
defined by NeuN-negativity (Fig. 5A). The mean infarct
area was reduced from 25.0  3.0% in vehicle-treated
mice (n = 12) to 8.9  1.2% in mice administered
10 mg/kg PAP-1 (n = 7, P = 0.0001) and to 7.3  1.7%
in mice administered 40 mg/kg PAP-1 (n = 9,
P = 0.0006).
As filament MCAO induces infarction not only in the
cortex, but also in the striatum, we used a 14 score tactile
and proprioceptive limb-placing test26 to evaluate mice in
a blinded fashion every 24 h. All mice exhibited scores of
~1 when tested 12 h after the surgery before drug admin-
istration was commenced (Fig. 5B). While vehicle-treated
animals only improved to an average score of 4 by day-4
and then leveled off (Fig. 5B), PAP-1 treatment
significantly improved neurological scores starting from
day-4 onwards. Mice treated with 10 mg/kg PAP-1 exhib-
ited a score of 7.2  0.43 (P = 0.0005 vs vehicle). Mice
treated with 40 mg/kg scored 8.6  1.20 (P = 0.0001 vs
vehicle) by day-8 of a maximal possible score of 14 for a
normal mouse.
Kv1.3 blockade preferentially reduces
inflammatory cytokine production but does
not affect phagocytosis of TUNEL-positive
Cells
We further determined brain cytokine levels on day-8 in
the ipsi- and contralateral hemisphere from vehicle-
treated sham-operated animals as well as vehicle- and
PAP-1-treated mice (40 mg/kg) subjected to MCAO
(Fig. 5C). MCAO significantly increased levels of the
Figure 4. PAP-1 reduces microglia activation and neuronal death in organotypic hippocampal mouse slices. (A) Hippocampal slices stained for
Iba-1 (green) and NeuN (red) 3 days after a 60 min exposure to hypoxia/aglycemia. PAP-1 (1 lmol/L) and minocycline (10 lmol/L) were added
2 h after the end of the hypoxia. (B) Quantification of data shown in (A) from five slices. Shown are means  S.E.M. (C) Western blot analysis for
PSD95 of lysates from control slices or slices exposed to hypoxia in the presence of absence of PAP-1 or minocycline.
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Figure 5. The Kv1.3 inhibitor PAP-1 reduces infarct area, improves neurological deficit, and reduces inflammatory cytokine production in mice.
(A) NeuN-defined infarct area in brain slices 2, 4, 6, and 8 mm from the frontal pole in vehicle-treated mice or mice treated intraperitoneally with
10 mg/kg or 40 mg/kg PAP-1 twice daily started 12 h after reperfusion. (B) Neurological deficit in the 14-score system (normal mouse = 14). (C)
Brain cytokine concentrations in the ipsi- and contralateral side 8 days after MCAO from vehicle or PAP-1 (40 mg/kg)-treated mice or shams
(n = 3). All values are mean  S.E.M.
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inflammatory cytokines IL-1b and IFN-c and of the
anti-inflammatory cytokine IL-10 in the infarcted hemi-
sphere. PAP-1 reduced IL-1b and IFN-c concentrations
without affecting IL-10 (Fig. 5C). PAP-1 also did not
reduce levels of brain-derived nerve growth factor
(BDNF) in both the ipsi- and contralateral side. We also
tried to measure TNF-a and IL-6, but found that levels
were below detection of the multiplex assay on day-8
after MCAO. Taken together, these findings suggest that
Kv1.3 inhibition preferentially reduces proinflammatory
cytokine levels.
As phagocytosis is a beneficial function of microglia,
which ideally should not be inhibited by a drug used for
stroke, we further investigated whether PAP-1 treatment
reduced the frequency at which CD68+ phagocytes in the
infarct area closely contacted TUNEL+ dying cells or had
incorporated TUNEL+ material (Fig. 6). In keeping with
our macroscopic observation that infarct areas in PAP-1-
treated mice are shrunken on day-8 after reperfusion
MCAO and not swollen like in mice where phagocytosis
is impaired (e.g., TREM2/ mice29), PAP-1 treatment at
both the low and the high dose did not reduce the per-
centage of CD68+ phagocytes closely contacting TUNEL+
cells or containing TUNEL+ material on day-8. However,
in animals treated with the higher dose of PAP-1, overall
fewer CD68+ phagocytes and less TUNEL+ staining was
observed (not shown), but the percentage of association/
internalization was not significantly changed (Fig. 6A).
The CD68+ cells containing TUNEL+ apoptotic cell mate-
rial mostly exhibited intact, regularly shaped nuclei
(Fig. 6B) when scanning through the cells in the confocal
images suggesting that the phagocytes themselves are not
undergoing apoptosis. These findings suggest that Kv1.3
inhibition does not affect phagocytosis in vivo confirming
a recent study reporting that Kv1.3 blockers to not impair
the ability of isolated brain mononuclear cells to phagocy-
tose polystyrene microspheres.38
Confirmation in a second species: PAP-1 also
reduces infarction and improves
neurological deficit in rats
Based on the difficulty of translating observations from
animal models of ischemic stroke into humans, any thera-
peutic finding should be reproduced in a second species.
We therefore also tested whether Kv1.3 inhibition with
PAP-1 could reduce infarction and improve neurological
deficit in rats. Male Wistar rats were subjected to 90 min
of MCAO with 8 days of reperfusion. Similar to mice and
humans, activated microglia in the infarct border zone,
identified by CD68 (= ED1) positivity, exhibited strong
Kv1.3 staining on iNOS+ microglia (Fig. 7A). PAP-1
treatment at 40 mg/kg started 12-hours after reperfusion
significantly reduced infarct area on day-8 (Fig. 7B) with
the mean infarct area being reduced from 23.0  5.2% in
vehicle-treated controls (n = 8) to 11.3  2.1% in PAP-
1-treated rats (n = 8, P = 0.03). The hemisphere shrink-
age was reduced from 9.2  2.3% in vehicle-treated con-
trols (n = 8) to 4.7  1.3% in PAP-1-treated rats (n = 8,
P = 0.07).
Rats were also evaluated for neurological deficit using
the same 14-score test26 described above for mice. In con-
trast to mice, rats were less severely affected by MCAO
and exhibited average scores of 3.2  0.4 when tested
12 h after the surgery before starting drug or vehicle
administration (Fig. 7C). Vehicle-treated rats improved to
an average score of 7.4  0.4 by day-5 and did not show
any further improvement until day-8 (Fig. 7C). PAP-1
treatment improved neurological scores starting from
day-4 onwards and rats in the PAP-1 group exhibited a
score of 10.1  0.7 (P = 0.023) by day-8.
Discussion
In addition to directly causing neuronal damage, acute
ischemic stroke elicits a strong neuroinflammatory
response. In both rodent models of cerebral ischemia and
in human postmortem brain, activated microglia/macro-
phages are abundant in the infarcted area between 18 and
96 h after the insult39 and are still present months and
sometimes even years after a stroke.40 PET imaging in
ischemic stroke patients demonstrated microglia activa-
tion in the peri-infarct zone on a similar time scale41 and
along affected pyramidal tracts for up to 6 months.42
Similar time courses for microglia activation with long-
term persistence have been reported for hemorrhagic
stroke and traumatic brain injury.43 Although microglia
can perform beneficial functions such as phagocytosing
debris and releasing neurotrophic factors, activated
microglia are also the main sources of inflammatory
cytokines, reactive oxygen species, and nitric oxide. In
rodent models, “M1-like” microglia have been described
to begin increasing around day-3 after MCAO and domi-
nate at 7 and 14 days after the insult, especially in the
infarct border, where they presumably expand neuronal
injury.44 Based on this delayed time course, modulation
of this secondary inflammatory damage has been pro-
posed as a more realistic target for stroke therapy21 than
acute neuroprotection, which has largely failed in the
clinic but is currently being reconsidered in the context
of reperfusion. So far a limited number of anti-inflamma-
tory therapies have advanced from animal studies to clini-
cal trials in acute ischemic stroke and intracerebral
hemorrhage. While enlimomab presumably failed due to
the use of a murine antibody, the IL-1 receptor antagonist
anakinra, the microglia inhibitor minocycline, and the
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sphingosine-1-phosphate receptor agonist fingolimod have
shown signs of efficacy in open-label Phase-II studies.45
Additionally, a large body of mechanistic work suggests
that more selective immunomodulatory therapies, espe-
cially approaches that have shown some efficacy in multi-
ple sclerosis or its animal models, should be evaluated in
Figure 6. Kv1.3 inhibition does not affect phagocytosis in vivo. (A) Sections obtained 4 mm from the frontal pole on day-8 after MCAO were
stained for activated microglia/macrophages with CD68 (green) and apoptosis associated TUNEL fragments (red). (B) Percentage of CD68+ cells
adjacent to or containing TUNEL+ material. Three fields along the edge of the infarct area were analyzed in each section (n = 3 animals per
treatment group). Values are mean  SD, P > 0.05. (C) Two-dimensional image showing DAPI, CD68 and TUNEL staining in a PAP-1 (10 mg/kg)-
treated mouse at higher magnification.
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stroke models.21,45 We here explored such an alternative
pharmacological target for immunomodulation in stroke
by demonstrating that the Kv1.3 inhibitor PAP-1 started
12 h after an ischemic insult reduces proinflammatory
cytokine levels in the infarcted hemisphere, and signifi-
cantly reduces infarct volume and improves neurological
deficit in two species. Although, this treatment window
should be further explored in future as Kv1.3 blockade
might still be effective when started at 24 or 48 h, it
clearly exceeds the 4.5 h for intravenous tissue plasmino-
gen activator and we consider these findings encouraging
as few experimental stroke treatments still show efficacy
when administered that late.
The exact mechanisms of how Kv1.3 inhibition reduces
infarction and neuroinflammation of course need to be
further investigated. Specifically, it will need to be sorted
out using tissue-specific knockouts whether effects on T-
cells and infiltrating monocytes contribute to the benefi-
cial actions of Kv1.3 inhibitors. Based on the observed
Kv1.3 expression on iNOS+ microglia/macrophages in
both rodents and humans and the finding that PAP-1
reduced IL-1b and IFN-c but not IL-10 and BDNF in the
postischemic brain, we propose that Kv1.3 inhibitors pref-
erentially suppress proinflammatory “M1-like” microglia
responses and spare beneficial microglia functions. This
hypothesis is supported by our recent mechanistic
in vitro studies showing that stimulation of cultured
mouse microglia with M1-polarizing stimuli greatly
increased Kv1.3 expression, while IL-4 treatment down-
regulated Kv1.3 and increased functional expression of
the inward-rectifier K+ channel Kir2.1.
19 In the same
study, PAP-1 reduced IL-1b, TNF-a and NO production
and reduced iNOS and COX-2 expression by LPS-stimu-
lated microglia, which is in keeping with the observed
Figure 7. Kv1.3 inhibition with PAP-1 reduces infarction and improves neurological deficit in rats. (A) Fluorescent staining for Kv1.3 and iNOS in
the border zone of an ischemic infarct from a rat, which contains many ED1 (= CD68) positive microglia/macrophages. (B) Infarct area in brain
slices 2, 4, 6, 8, 10, 12 and 16 mm from the frontal pole in vehicle-treated rats or rats treated with 40 mg/kg PAP-1 twice daily started 12 h
after reperfusion. (C) Neurological deficit in the 14-score system (normal rat = 14). Values are mean  S.E.M.
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reduction in hypoxia-stimulated microglia activation by
PAP-1 in organotypic hippocampal slices in our current
study, where no infiltration of blood-derived monocytes
or T-cells is possible. However, we can of course not
completely exclude effects of PAP-1 on T-cells and infil-
trating monocytes in vivo, but would like to point out
that they are also likely beneficial given the fact that
Kv1.3 inhibitors, similar to fingolimod, effectively treat
rodent models of multiple sclerosis and other memory T-
cell-mediated autoimmune diseases.4
As pointed out by a reviewer, we can further not com-
pletely rule out PAP-1 effects on other Kv1-family chan-
nels such as Kv1.2 and Kv1.5. However, we would like to
point out that PAP-1 inhibits Kv1.3 with an IC50 of
2 nmol/L, while the IC50 for Kv1.2 is 250 nmol/L.
22 Phar-
macokinetic studies using UPLC/MS have shown that
total PAP-1 brain concentrations peak between 2 and
10 lmol/L at 2 h after administration of 10 or 40 mg/kg
but that brain concentrations for most of the 12-h time
period between drug administrations are in the range of
200 nmol/L to 1 lmol/L. Considering PAP-1’s plasma
protein binding of 98%, these total concentrations trans-
late to effective free concentrations of 40–200 nmol/L at
the Cmax and of 4–20 nmol/L for most of the time in this
study.4,23 We therefore believe that Kv1.2 inhibition is
not likely to significantly contribute to the effects of PAP-
1. Kv1.5, which PAP-1 inhibits with an IC50 of 45 nmol/
L22 is more likely to contribute. However, despite previ-
ous reports of Kv1.5 expression in microglia,46 we have
not been able to detect Kv1.5 message in cultured micro-
glia from C57BL6 mice19 and can only speculate that
there is a strain difference between C57BL6 and the 129S6
background of the Kv1.5/ mice.46 We further previ-
ously observed16 that the Kv current in acutely isolated
microglia from MCAO mice is not only blocked by PAP-
1 but also by 100 pM ShK-L5, a peptidic inhibitor of
Kv1.3, that has no effect on Kv1.5.47 However, we are
sure that inhibition other microglia ionic currents such as
KCa3.1 currents or Hv1-mediated proton currents does
not contribute to the PAP-1 effects. PAP-1 exhibits 5000-
fold selectivity for Kv1.3 over KCa3.122 and, as we
recently tested based on a reviewer suggestion, does not
affect proton currents in primary mouse microglia at con-
centrations of 1 and 10 lmol/L (data not shown).
When proposing that Kv1.3 inhibitors preferentially
inhibit “M1-like” inflammatory microglia/macrophage
functions and preserve beneficial “M2-like” functions, we
are fully cognizant of the fact that microglia are highly
plastic and, unlike T-cells, do not achieve stable differen-
tiation states.48 Yet, our results seem to support this
simple therapeutic hypothesis by showing that the
observed reduction in infarct area and improvement in
neurological deficit following PAP-1 treatment is
accompanied by a reduction in brain levels of IL-1b and
IFN-c, but not IL-10 and BDNF or an impairment of
phagocytosis. Another attractive feature of using Kv1.3
inhibitors to reduce neuroinflammation in the wake of
ischemic stroke is that Kv1.3 inhibitors are known to be
immunomodulators rather than immunosuppressants
and do not impair the ability of rodents to clear acute
infections or of primates to develop vaccine responses.5,8
Kv1.3 inhibitors are therefore unlikely to further increase
the risk of respiratory and urinary tract infections, which
are responsible for considerable morbidity and mortality
after stroke.45,49 This phenomenon, which manifests as
lymphopenia in stroke patients and rodent models, is
mediated by an increased release of cortisol and cate-
cholamines,49 which has recently been shown to induce
a higher bone marrow output of inflammatory mono-
cytes and neutrophils and a drastic reduction in lym-
phoid progenitors.50 In addition, KV1.3 blockade seems
to be relatively safe and well tolerated. Toxicity studies
with PAP-1 and the peptidic KV1.3 blocker ShK-186
have so far not revealed any toxicity despite 6 months
or 28 days of continuous administration in rats or rhe-
sus macaques.4,8 PAP-1 has further completed IND-
enabling toxicity studies, while ShK-186 has passed both
IND toxicity studies and Phase-1 safety studies without
any adverse findings.6,9
In conclusion, we are proposing Kv1.3 inhibitors as
novel potential therapeutics for reducing secondary
inflammatory damage in ischemic stroke by preferentially
targeting “M1-like” microglia functions. Following this
first pharmacological proof-of-concept study, PAP-1 and
other small molecule Kv1.3 blockers should be further
explored in alternative stroke models, that for example
establish reperfusion with alteplase to increase translata-
bility to human stroke, and also be studied in females
and animals with comorbidities.
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